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IntRoductIon
Interest in developing new drugs for the 
treatment of acute heart failure (AHF) re-
mains high and the past, present and future 
of diuretics, vasodilators and inotropes is 
source of debate and expectations (1). 
Among these three drug therapies, is the 
inotropic one which is raising the most 
controversies (2). While waiting for new 
promising drugs to be confirmed as serious 
players (3), the present manuscript aims to 
review the latest addition to the available 
repertoire of inotropes and inodilators, le-
vosimendan (Figure 1).
Levosimendan is an inodilator developed 
for intravenous use in hospitalised patients 
with acutely decompensated heart failure 
(ADHF). The pharmacological effects of 
levosimendan are:
a) increased cardiac contractility mediated 
by calcium sensitisation of troponin C 
(4-8);
b) vasodilation through the opening of po-
tassium channels on the sarcolemma of 
smooth muscle cells in the vasculature 
(9-12);
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ABStRAct
Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic 
heart failure, and in situations where conventional therapy is not considered adequate. The principal pharma-
cological effects of levosimendan are (a) increased cardiac contractility by calcium sensitisation of troponin 
C, (b) vasodilation, and (c) cardioprotection. These last two effects are related to the opening of sarcolemmal 
and mitochondrial potassium-ATP channels, respectively. Data from clinical trials indicate that levosimendan 
improves haemodynamics with no attendant significant increase in cardiac oxygen consumption and relieves 
symptoms of acute heart failure; these effects are not impaired or attenuated by the concomitant use of beta-
blockers. Levosimendan also has favourable effects on neurohormone levels in heart failure patients. Levosi-
mendan is generally well tolerated in acute heart failure patients: the most common adverse events encountered 
in this setting are hypotension, headache, atrial fibrillation, hypokalaemia and tachycardia. Levosimendan has 
also been studied in other therapeutic applications, particularly cardiac surgery - in which it has shown a range 
of beneficial haemodynamic and cardioprotective effects, and a favourable influence on clinical outcomes - and 
has been evaluated in repetitive dosing protocols in patients with advanced chronic heart failure. Levosimen-
dan has shown preliminary positive effects in a range of conditions requiring inotropic support, including right 
ventricular failure, cardiogenic shock, septic shock, and Takotsubo cardiomyopathy.
Keywords: levosimendan, acute heart failure, cardiac surgery, cardioprotective inodilator, review, shock.
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under beta-blockade (17, 26). Levosimen-
dan offers a predictable safety profile (17-
19, 23), no impairment of diastolic func-
tion (27, 28), with no development of 
tolerance (25). The most common adverse 
events are hypotension, headache, atrial 
fibrillation, hypokalemia and tachycardia 
(22, 23, 29).
Levosimendan is indicated for the short-
term treatment of acutely decompensated 
severe chronic heart failure in situations 
where conventional therapy is not suf-
ficient, and in cases where inotropic sup-
port is considered appropriate. In the latest 
decade, however, levosimendan has been 
studied in numerous clinical trials outside 
the field of acute heart failure. Primarily, 
the drug has been tested in the cardiac sur-
gery settings (30), field in which the drug 
has shown beneficial haemodynamic and 
cardioprotective effects and a favorable 
outcome effect. In addition, several stud-
ies with repetitive levosimendan dosing in 
patients suffering from advanced chronic 
heart failure have shown beneficial effects 
on haemodynamics, neurohormone levels 
and symptoms (31). Finally, levosimendan 
has also shown preliminary positive effects 
- mainly in small-scale studies - in right 
ventricular failure, cardiogenic shock, sep-
tic shock, Takotsubo cardiomyopathy, and 
in other states requiring inotropic support 
(32, 33). Our aim is to review the current 
data, clinical use and future development 
of levosimendan in all therapy settings en-
visioning the future development for this 
drug, the first in class of the cardioprotec-
tive inodilators.
clInIcAl dEVEloPMEnt
Most of the studies in the regulatory clini-
cal development of levosimendan were 
(Table 1) performed in patients with acute 
worsening of chronic heart failure. The 
table 1 - Trial acronyms.
AlARM-HF Acute Heart Failure Global Survey 
of Standard Treatment 
lIdo Levosimendan Infusion versus Do-
butamine
levoRep Randomised trial investigating the 
efficacy and safety of pulsed infu-
sions of levosimendan in outpa-
tients with advanced heart failure
REVIVE I 
and II
Randomized Multicenter Evalua-
tion of Intravenous Levosimendan 
Efficacy trials I and II
RuSSlAn Randomized Study on Safety and 
Effectiveness of Levosimendan in 
Patients with Left Ventricular Fai-
lure after an Acute Myocardial In-
farct 
SuRVIVE Survival of Patients with Acute He-
art Failure in Need of Intravenous 
Inotropic Support
Figure 1 - Chemical structure of levosimendan, the 
(-) enantiomer of {[4-(1,4,5,6-tetrahydro-4-methyl-
6-oxo-3-pyridazinyl)phenyl]hydrazono}propan-
edinitrile.
c) cardioprotection through the opening 
of mitochondrial potassium channels in 
the cardiomyocytes (13-16).
Clinical data from heart failure patients 
show that levosimendan improves hae-
modynamics (17-19) without a significant 
increase in oxygen consumption (20, 21), 
reduces symptoms of AHF (17, 18, 22, 23), 
has a beneficial effect on neurohormone 
levels (22-24), has a sustained efficacy due 
to formation of an active metabolite (24, 
25), and suffers no loss of effect in patients 
Levosimendan
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regulatory clinical development program 
included about 3,500 patients.
Dose-finding study
The therapeutic dose range of levosimendan 
administered over a 24 h period was identi-
fied in a double-blind, placebo-controlled 
study including 151 patients with stable 
(mainly NYHA class III) heart failure of 
ischaemic origin. Patients were treated with 
a bolus dose of levosimendan of 3-36 µg/kg 
in 10 min followed by a 24 h intravenous 
infusion at doses ranging from 0.05 to 0.6 
μg/kg/min (19).
Dose escalation study
Up-titration, maintenance and withdrawal 
of levosimendan were studied in a ran-
domised, double-blind, placebo-controlled 
study in 146 patients hospitalised for de-
compensated heart failure (NYHA class III 
or IV) due to coronary artery disease (60%) 
or dilated cardiomyopathy (40%) (18). Pa-
tients received an intravenous infusion of 
levosimendan at doses ranging from 0.1 to 
0.4 μg/kg/min. 
The study was divided into three phases. 
During the first 6 h, escalated doses of le-
vosimendan (n=98) were compared with 
placebo (n=48). From 6 to 24 h, patients 
in the levosimendan group continued to re-
ceive the study medication as an open-label 
infusion. At 24 h, the patients remaining 
in the study were randomised to continue 
on levosimendan (levosimendan continua-
tion group) or placebo (levosimendan with-
drawal group), administered double-blind 
up to 48 h (18, 25).
LIDO study
Levosimendan was compared with dobuta-
mine in the LIDO (Levosimendan Infusion 
versus Dobutamine) study, a double-blind, 
randomised study in 203 patients with low-
output heart failure, who required right 
heart catheterisation and treatment with 
an intravenous inotropic drug. Patients 
randomised to levosimendan were treated 
with an initial intravenous bolus of 24 μg/
kg in 10 min, followed by a 24 h intrave-
nous infusion of levosimendan at doses 
from 0.1 to 0.2 μg/kg/min (17).
RUSSLAN study
The safety of levosimendan in patients 
with left ventricular failure complicating 
an acute myocardial infarction was stud-
ied in RUSSLAN (Randomised Study on 
Safety and Effectiveness of Levosimendan 
in Patients with Left Ventricular Failure 
after an Acute Myocardial Infarct), a place-
bo-controlled, double-blind, parallel-group, 
randomised study in 504 patients enrolled 
within 5 days of an index infarction (34). 
Patients randomised to levosimendan were 
treated with a bolus dose of 6-24 μg/kg in 
10 min, followed by a 6-h intravenous in-
fusion at rates ranging from 0.1 to 0.4 μg/
kg/min. Invasive haemodynamic data were 
not collected.
REVIVE studies
The REVIVE (Randomised Multicenter 
Evaluation of Intravenous Levosimendan 
Efficacy) studies (REVIVE I and REVIVE 
II) evaluated the efficacy of levosimendan 
on symptoms of heart failure by means of 
a composite endpoint comprising patients’ 
subjective symptom assessments (at 6 h, 
24 h and 5 days) and signs of worsening 
symptoms (including death) during the 5 
days after starting a 24 h trial drug infu-
sion. These two randomised, double-blind, 
placebo-controlled, parallel-group studies 
in patients with ADHF were conducted 
mainly in the USA. REVIVE I (n=100) 
was a pilot study designed to evaluate the 
suitability of the chosen composite (35); 
REVIVE II (n=600) was a phase III study 
(22). Patients randomised to levosimendan 
(given in addition to current medications) 
received an initial bolus of 6-12 μg/kg in 10 
230
M.S. Nieminen, et al.
Heart, Lung and Vessels. 2013, Vol. 5
min, followed by a 24 h intravenous infu-
sion at rates of 0.1 to 0.2 μg/kg/min.
SURVIVE study
The SURVIVE (Survival of Patients with 
Acute Heart Failure in Need of Intra-
venous Inotropic Support) study was a 
double-blind, randomised study in 1327 
patients with severe systolic heart failure 
comparing the effects of levosimendan 
with dobutamine on mortality. Patients in 
the levosimendan arm were treated (on top 
of current AHF medications) with a bolus 
of 12 μg/kg in 10 min, followed by a 24 h 
intravenous infusion of 0.1 to 0.2 μg/kg/
min (23).
MAIn tHERAPEutIc EFFIcAcY 
And SAFEtY dAtA
Haemodynamics
Levosimendan has repeatedly been shown 
to produce significant dose-dependent in-
creases in cardiac output, stroke volume 
and heart rate, and decreases in pulmo-
nary capillary wedge pressure, mean blood 
pressure, mean pulmonary artery pressure, 
mean right atrial pressure and total periph-
eral resistance (19).
The effect of levosimendan on haemody-
namic variables (cardiac output, stroke vol-
ume, heart rate and pulmonary capillary 
wedge pressure) are clearly evident already 
at the end of a 5 min bolus infusion (36). 
There is no sign of development of toler-
ance even with a prolonged infusion up to 
48 h (25). Haemodynamic effects are main-
tained up to 7-9 days after stopping levosi-
mendan infusion, due to the formation of 
an active metabolite, designated OR-1896 
(24).
Compared with dobutamine, levosimendan 
produces a slightly greater increase in car-
diac output and a profoundly greater de-
crease in pulmonary capillary wedge pres-
sure (17, 37). In contrast to dobutamine, 
the haemodynamic effects are not attenuat-
ed with concomitant beta-blocker use (17). 
At 48 h after the start of infusion in beta-
blocked patients with severe ADHF, a 24 
h infusion of levosimendan achieves better 
haemodynamic effects than a 48 h dobuta-
mine infusion (37).
Blood pressure
The data from REVIVE show that levosi-
mendan significantly decreases blood pres-
sure compared to placebo (22). Accord-
ingly, the current Summary of Product 
Characteristics (SPC) labelling suggests 
levosimendan be used with caution in pa-
tients with low baseline systolic or diastolic 
blood pressure or those at risk for a hypo-
tensive episode. 
Post-hoc analyses of the REVIVE stud-
ies identified systolic blood pressure <100 
mmHg or diastolic blood pressure <60 
mmHg at baseline as a factor increasing mor-
tality risk (22, 38). Conversely, in patients 
with higher blood pressure at baseline (sys-
tolic ≥100 mmHg and diastolic ≥60 mmHg), 
mortality was 8% with levosimendan and 
9% with placebo (p=0.81). Of importance 
is the finding that the primary composite 
endpoint was still positive and statistically 
significant in this subgroup (38).
Symptoms
Dyspnoea improved in significantly more 
patients treated with levosimendan com-
pared with placebo at 6 hours after the start 
of treatmentin one early controlled trial 
in severe heart failure (18). On the other 
hand, in the LIDO study (17), symptoms 
of dyspnoea and fatigue improved equally 
well in levosimendan-or dobutamine-treat-
ed patients at 24 h after the start of infu-
sion.
In the REVIVE II study, symptoms over 
the 5-day assessment period improved sig-
nificantly more with levosimendan than 
Levosimendan
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with placebo (22). It should be noted that 
in REVIVE levosimendan (or placebo) was 
administered on top of the standard of care 
and that in the placebo group, the majority 
of the patients also improved vs baseline.
Composite end point
In the REVIVE II study, the primary end-
point was a composite consisting of pa-
tients’ subjective symptom assessments (at 
6 hours, 24 hours, and 5 days) and signs 
of worsening symptoms (including death) 
during the 5 days after starting a 24-h trial 
drug infusion. Improvement was observed 
more frequently (19% vs 15%) and wors-
ening less frequently (19% vs 27%) in levo-
simendan treated patients compared with 
placebo (p=0.015) (22). The improvement 
in the composite endpoint was accompa-
nied by a lower need for rescue medication 
in the levosimendan group (22, 38).
Neurohormones
Several studies indicate that levosimendan 
produces a rapid and sustained decrease 
in natriuretic peptides. Lilleberg et al. (24) 
found that a 24-h levosimendan infusion 
induced a 40% decrease in plasma N-termi-
nal atrial natriuretic peptide and N-termi-
nal pro-BNP (NT-proBNP) levels and the 
treatment effect was estimated to last up to 
16 and 12 days, respectively. In the SUR-
VIVE study, a similar decrease in BNP was 
seen (23) but duration of the effect could 
not be determined as the last time-point for 
measuring BNP was 5 days. In the REVIVE 
II study the significant effect on BNP was 
also evident until day 5 (22).
Mortality
In the LIDO study, mortality was followed 
as a secondary endpoint for 31 days. Dur-
ing that time, 8% of patients assigned to 
levosimendan died, compared with 17% 
assigned to dobutamine (p=0.049). The 
follow-up was retrospectively extended to 
180 days, at which point the respective fig-
ures were 26% for levosimendan and 38% 
for dobutamine (p=0.029) (17). Mortality 
in the RUSSLAN study (34) was prospec-
tively followed for 14 days after starting 
treatment and shown to be significantly 
lower with levosimendan than with pla-
cebo (12% vs 20%; p=0.031). There was 
a trend for this positive effect to persist 
up to 180 days in a retrospective analysis 
(23% vs 31%; p=0.053). In the REVIVE 
II study (22), mortality was numerically, 
but not statistically significantly, higher in 
the levosimendan group, with 45 (15%) 
deaths in the levosimendan group and 35 
(12%) in the placebo group during the 90-
day study period (p=0.21). In the SUR-
VIVE study (23) there was no significant 
difference in survival between levosimen-
dan and dobutamine (26% vs 28%, hazard 
ratio 0.91; 95% CI, 0.74-1.13; p=0.40). A 
majority (88%) of patients in this study 
had a history of ADHF. In these patients, 
mortality at 31 days was significantly lower 
with levosimendan than with dobutamine 
(p=0.046) (26). Similarly, mortality was 
significantly lower with levosimendan than 
with dobutamine in the subset of patients 
receiving concomitant beta-blockers (26).
Several meta-analyses on the effect of levo-
simendan on mortality have been recently 
published (39-44). Among these, the inves-
tigation by Landoni et al. (40) is the most 
comprehensive and statistically the most 
robust. It included 45 clinical trials with 
intravenous levosimendan with a total of 
5480 patients. Levosimendan significantly 
reduced mortality both in cardiology and 
cardiac surgery settings, and both against 
dobutamine and placebo.
A registry study, ALARM-HF (Acute Heart 
Failure Global Survey of Standard Treat-
ment), reviewed in-hospital treatments in 
eight countries (45). Unadjusted analysis 
showed a significantly higher in-hospital 
mortality rate in patients receiving intra-
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venous inotropes (25.9%) compared to 
those who did not (5.2%) (p<0.0001). A 
propensity-based analysis was performed 
to compare in-hospital mortality in patients 
treated only with intravenous levosimen-
dan versus those treated only with catechol-
amines within 24 h of therapy initiation. 
Propensity score matching produced 104 
matched pairs and showed that the use of 
levosimendan resulted in a significant re-
duction in the risk of in-hospital mortality 
(hazard ratio 0.25, 95% CI 0.07-0.85).
Hospitalization
A way to evaluate the effect of a medica-
tion on both mortality and morbidity is to 
assess the number of days a patient is both 
alive and out of hospital during the follow-
up period. In the LIDO study, patients in 
the levosimendan group spent significantly 
more days alive and out of hospital than 
dobutamine-treated patients in a retrospec-
tive 180-day follow-up analysis (median 
157 vs 133 days for levosimendan and do-
butamine, respectively; p=0.027) (17). 
In the REVIVE II study, the mean dura-
tion of the initial hospitalisation was al-
most 2  days shorter in the levosimendan 
group (7.0 days) than in the placebo group 
(8.9 days) (22, 38). Significantly more pa-
tients treated with levosimendan were re-
leased within 5 days and fewer had extend-
ed hospitalisations (p=0.008). 
In a recent single center study (46) that 
compared levosimendan with standard 
of care in a population of AHF patients, 
the mean length of hospitalization was 
12.1 and 13.6 days in the levosimendan 
(n=147) and control groups (n=147), re-
spectively (p<0.05). Re-hospitalization 
rates were lower in the levosimendan group 
at 12 months (7.6 vs 14.3%; p<0.05), and 
mortality rates at 1 month were 2.1% vs 
6.9%, respectively (p<0.05). In confor-
mity with these observations from individ-
ual studies, in the earlier-mentioned meta-
analysis by Landoni et al. (40) the mean 
length of stay in hospital was 1.59 (95% CI 
0.85-2.33) days shorter in levosimendan-
treated patients in the cardiology setting 
(p<0.0001).
Renal function
Renal function often worsens in patients 
with AHF, and this deterioration is asso-
ciated with adverse outcome. Studies show 
improved serum creatinine levels in levosi-
mendan-treated patients (47, 48).
Estimated glomerular filtration rate (eGFR) 
improved in levosimendan compared to do-
butamine treated patients with heart fail-
ure who required inotropic therapy (49). A 
placebo-controlled study in patients hospi-
talized for decompensated heart failure and 
renal dysfunction, showed a statistically 
significant improvement in eGFR in levo-
simendan treated patients. Peak effect was 
seen at 3 days after a 24-h infusion, with 
discernible effects persisting up to 14 days 
(50). In addition to beneficial effects on cen-
tral hemodynamics, levosimendan has di-
rect effects on renal circulation and induces 
preglomerular vasodilation (51), leading to 
improved renal blood flow and glomerular 
filtration rate (52). The renal oxygen de-
mand/supply relationship is not affected by 
levosimendan (51). In a meta-analysis of 4 
randomized studies on the effect of levosi-
mendan in cardiac surgery, a reduction in 
the rate of acute renal failure was seen in fa-
vor of levosimendan treated patients (odds 
ratio 0.26 [96% CI 0.12-0.60], p=0.002, 
with 228 patients included) (53). Interest-
ingly study was just started on the effect of 
Levosimendan in Acute Kidney Injury (LA-
KIS, NCT01720030).
Severe renal failure is a contraindication 
for levosimendan use as no formal phar-
macokinetic studies in heart failure pa-
tients with severe renal failure have been 
conducted. However, many heart failure 
patients in large regulatory studies such 
Levosimendan
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as REVIVE and SURVIVE had severe re-
nal failure (22, 23, 26). According to phar-
macokinetic study in severe renal impair-
ment, the elimination of the levosimendan 
metabolites was prolonged. The results 
suggest that if levosimendan was given to 
heart failure patients with severe renal im-
pairment, the dose should be reduced (54).
Effects on other organs
Some reports on a positive effect of levosi-
mendan on splanchnic (55), liver (56, 57), 
and diaphragm functions (58) have been 
published. It must be highlighted, howev-
er, that these data were not collected in an 
AHF population, but in other settings, such 
as septic shock, cardiac surgery, or chronic 
obstructive pulmonary disease (COPD). 
Adverse events
Levosimendan infusion has generally been 
well tolerated in the AHF population, de-
spite the high-risk nature of these patients. 
Hypotension was seen more frequently 
with levosimendan than with placebo (22), 
but not when levosimendan was compared 
with dobutamine (23). Levosimendan has 
been associated with a higher incidence of 
atrial fibrillation compared both with pla-
cebo (22) and with dobutamine (23). How-
ever, conflicting results have been present-
ed with regard to ventricular arrhythmias. 
In REVIVE a higher incidence of ventricu-
lar tachycardia was observed with levosi-
mendan compared with placebo (22). In 
SURVIVE, ventricular tachycardia was ob-
served with similar frequency in the levo-
simendan and dobutamine groups (23). In 
both studies, cardiac failure as an adverse 
event was less frequent in levosimendan 
arm, although the result was statistically 
significant only in SURVIVE.
Safety laboratory values
The changes in safety laboratory variables 
have been modest in levosimendan studies. 
A decrease in potassium levels has been 
seen with levosimendan more often than 
with comparators (19). Clinically insignifi-
cant decreases in haemoglobin and erythro-
cyte counts have been observed (19). 
clInIcAl tRIAlS SEttInGS 
otHER tHAn AdHF
During the past years, various indepen-
dent research groups have described the 
use of levosimendan in a range of clinical 
situations other than ADHF, e.g. advanced 
chronic heart failure, cardiogenic- and sep-
tic-shock, cardiac- and non-cardiac surgery, 
etc. Hereby we review the most recent lit-
erature.
Advanced chronic heart failure
Patients with refractory heart failure are 
hospitalised frequently for clinical dete-
rioration. During such admissions, they 
often receive infusions of positive inotro-
pes (dobutamine, dopamine, or milrinone) 
and vasodilators in an effort to improve 
cardiac performance, facilitate diuresis and 
promote clinical stability (59). Despite fa-
vourable haemodynamic and symptomatic 
improvement in small clinical studies, con-
cerns have been raised about the safety of 
intermittent or continuous inotropic ther-
apy. Both dobutamine and milrinone in-
crease the myocardial oxygen demand and 
intracellular calcium concentration, thus 
increasing the risk of arrhythmic events 
and, possibly, death (60, 61). A number of 
small-scale investigator-initiated studies, 
in which levosimendan has been adminis-
tered repeatedly to patients with advanced 
chronic heart failure, have been reported 
and are summarized below. In general, the 
results suggest that levosimendan improves 
haemodynamics, neurohormones and clini-
cal outcomes. However, the optimal dosing 
scheme has not been established.
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Nanas et al. (62) exposed 36 consecutive 
patients with NYHA class IV heart failure, 
resistant to a 24 h continuous infusion of 
dobutamine: a group was exposed to con-
tinuous infusion of dobutamine 10 mg/kg/
min for at least 48 h, followed by weekly 
(or more often if needed) intermittent do-
butamine infusions of 8 h (n=18) while 
the second group, after the initial 24 h infu-
sion of dobutamine, to a 24 h infusion of 
levosimendan (0.2 mg/kg/min) followed by 
further biweekly 24 h infusions at the same 
dose. The addition of intermittent levosi-
mendan infusions was associated with a 
prolonged survival (45-day survival of 6% 
vs 61%; p=0.0002).
Mavrogeni et al. (63) performed an open-
label prospective study in 50 patients with 
advanced heart failure (NYHA III or IV). 
Half of the patients received 24 h infusions 
of levosimendan (0.1-0.2 mg/kg/min after a 
6 mg/kg loading dose) given monthly for 6 
months in addition to standard of care and 
half of the patients were treated with stan-
dard of care. At the end of the study, the 
proportion of patients reporting improve-
ment in symptoms of heart failure was 
larger in the levosimendan group than in 
the control group (65% vs 20%; p<0.01). 
After 6 months, the levosimendan group 
had a significant increase in left ventricu-
lar ejection fraction (LVEF) (28±7% vs 
controls 21±4%; p=0.003). Twenty-four 
hours Holter-recordings revealed no signif-
icant changes in the occurrence of atrial or 
ventricular arrhythmias between the two 
groups. Two patients in the levosimendan 
group died during the 6-month follow-up 
period, compared with 8 patients in the 
control group (p<0.05) (63).
Parle et al. (64) reported on 44 consecu-
tive heart failure patients with systolic im-
pairment, who received between 2 and 26 
repeated infusions of levosimendan. The 
bolus dose was omitted in 65% of admin-
istrations and the maximum maintenance 
infusion was 0.2 mg/kg/min in 60% of pa-
tients. The interpretation of efficacy and 
safety is hampered by the absence of a con-
trol group. However, a significant drop in 
BNP levels and NYHA class was observed 
and overall the infusions were judged to be 
well-tolerated. 
Parissis et al. (65) performed an open-label, 
randomised, placebo-controlled study in 25 
patients with decompensated chronic heart 
failure. Five 24 h infusions of levosimen-
dan (a bolus of 6 mg/kg/10 min followed 
by an infusion of 0.1 mg/kg/min) were 
given to 17 patients in a 3 weeks interval. 
Levosimendan treatment was accompa-
nied by significant reductions in cardiac 
end-systolic and end-diastolic dimensions 
and volume indices (p<0.01 vs baseline). 
LVEF was significantly enhanced and left 
ventricular end-systolic wall stress was re-
duced. Significant reductions in NT-proB-
NP (p<0.01), high-sensitivity C-reactive 
protein (p<0.01) and plasma interleukin-6 
(p=0.05) were observed in the levosimen-
dan group. The number of patients with a 
positive troponin T (≥ 0.01 ng/ml) did not 
differ between the two groups at baseline, 
but was significantly higher in the place-
bo-treated group at the final evaluation 
(p<0.05). In the placebo group, no statis-
tically significant improvements in any of 
the variables were seen.
The effects of long-term, intermittent treat-
ment of levosimendan, dobutamine, and 
the combination of levosimendan with do-
butamine on outcomes have recently been 
studied in 63 patients with decompensated 
end-stage heart failure. Three groups, each 
of 21 patients, were assigned to dobuta-
mine 10 mg/kg/min, to levosimendan 0.3 
mg/kg/min, or to dobutamine 10 mg/kg/
min and concomitant levosimendan 0.2 
mg/kg/min. The durations of the infusions 
were 6 h, and the drugs were given weekly 
for 6 months. In addition, all patients re-
ceived oral amiodarone (400 mg/day). The 
Levosimendan
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6-month survival was 80% in the levosi-
mendan-only group, 48% in the dobuta-
mine-only group and 43% in the combined 
group. Cardiac index was significantly in-
creased and pulmonary capillary wedge 
pressure significantly decreased only in the 
levosimendan group (66).
Moreover, a study was conducted in 28 
patients with pulmonary hypertension of 
various etiologies (including secondary to 
left-sided heart failure) (67). Patients were 
randomised 2:1 to levosimendan and place-
bo and they received in total five infusions. 
The initial 24 h levosimendan infusion (12 
mg/kg bolus followed by the maintenance 
infusion of 0.1-0.2 mg/kg/min) produced a 
significant decrease in pulmonary vascular 
resistance. Thereafter, levosimendan was 
administered every 2 weeks as a 6-h infu-
sion with the infusion rate of 0.2 mg/kg/
min. These repeated administrations were 
found to be safe and the effect on pulmo-
nary vascular resistance was maintained 
throughout the course of treatment.
Finally, the largest study with repetitive 
dosing with levosimendan is the LevoRep 
(Randomised trial investigating the effi-
cacy and safety of pulsed infusions of le-
vosimendan in outpatients with advanced 
heart failure) study (31), a randomised, 
double-blind, placebo-controlled study 
in advanced chronic heart failure. Levo-
simendan was administered as 6-h infu-
sions (0.2 mg/kg/min) every 2 weeks for 
8 weeks (four infusions per patient). Pub-
lication of the final results of LevoRep is 
awaited. Meanwhile, three similar stud-
ies has been started: the Intermittent In-
travenous Levosimendan in Ambulatory 
Advanced Chronic Heart Failure Patients 
study (LION-HEART, NCT01536132), 
the Randomized, Double-Blind, Placebo 
Controlled, Multicenter Trial to Study Ef-
ficacy, Security, and Long Term Effects of 
Intermittent Repeated Levosimendan Ad-
ministration in Patients with Advanced 
Heart Failure (LAICA, NCT00988806), 
and the Early LEvosimendanVs Usual 
Care in Advanced Chronic hearTfailurE 
(ELEVATE, NCT01290146).
Right ventricular failure
Right ventricular failure is most common-
ly related to left ventricular heart failure. 
Biventricular failure has a worse outcome 
than pure left ventricular failure. In iso-
lated right ventricular failure there is low 
output syndrome in the absence of pulmo-
nary congestion, with increased jugular 
venous pressure, with or without hepatic 
congestion, and a low left ventricular fill-
ing pressure. Right ventricular failure can 
be caused by myocardial ischemia, volume 
overload and/or pressure overload (68). In-
vestigator initiated studies have been per-
formed in patients with right ventricular 
failure. In these studies, levosimendan has 
been shown to:
1) reduce the increased right ventricular 
afterload;
2) improve right ventricular contractility;
3) improve diastolic function of the right 
ventricle.
Parissis et al. (69) reported that, in a pla-
cebo-controlled study in 54 patients with 
advanced right ventricular heart failure 
(NYHA III-IV, LVEF <35%), levosimen-
dan (0.1-0.2 μg/kg/min for 24 h) improved 
Doppler echocardiographic markers of sys-
tolic and diastolic right ventricular func-
tion. Poelzl et al. (70) administered open-
label levosimendan (bolus in the range of 
6-12 μg/kg and infusion in the range of 
0.075-0.2 μg/kg/min for 24 h) to 18 pa-
tients with AHF (characterized by LVEF 
≤30%, cardiac index ≤2.5 l/min/m2, right 
atrial pressure ≥10  mmHg, pulmonary 
capillary wedge pressure ≥15 mmHg) and 
observed improved right ventricular con-
tractility but not any change in right ven-
tricular afterload.
Russ et al. (71) evaluated right ventricular
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function in 25 consecutive acute myocar-
dial infarction patients with cardiogenic 
shock not responding sufficiently to con-
ventional treatment. A 24 h levosimendan
infusion (12 μg/kg bolus in 10 min, fol-
lowed by a dose of 0.1-0.2 μg/kg/ min) de-
creased pulmonary vascular resistance and 
improved cardiac power index (both right 
and left ventricles), indicating decreased 
right ventricular afterload and improved 
right ventricular contractility.
Morelli et al. (72) studied 35 mechanically 
ventilated patients with acute respiratory 
distress syndrome (ARDS) related to sep-
tic shock. Patients were treated with a 24 h 
infusion of levosimendan (0.2 μg/kg/min, 
n=18) or placebo (n=17). Reductions in 
pulmonary vascular resistance and mean 
pulmonary arterial pressure, and improve-
ments in cardiac index, right ventricular 
ejection fraction and mixed venous oxygen 
saturation were observed only in the levo-
simendan group.
Cardiogenic shock 
Cardiogenic shock is a rare but often fatal 
complication of acute coronary syndrome. 
The underlying pathophysiology is pro-
found depression of myocardial contractil-
ity and the state can be defined as decreased 
cardiac output and evidence of tissue hy-
poxia in the presence of adequate intravas-
cular volume (73). The standard of care 
consists of primary percutaneous coronary 
intervention for ST-elevated myocardial 
infarction, fluid therapy, vasopressors and 
inotropes (74). The role of intra-aortic bal-
loon pump (IABP) counter-pulsation has 
recently been challenged (75). Data de-
scribing the use of levosimendan in cardio-
genic shock are still scarce. Nevertheless, 
the drug appears to be safe and to improve 
some haemodynamic and ventricular in-
dices (69, 76-78). The improved survival 
reported by Fuhrmann et al. (79) is nota-
ble (30 day survival 69% with levosimen-
dan vs 37% with enoximone; p=0.023, 
n=32), but the current dataset is too small 
to draw definitive conclusions.
Septic shock
Sepsis and septic shock are among the lead-
ing causes of death in intensive care units 
(ICUs) with associated mortality rates up to 
~50% (80). Sepsis frequently causes myo-
cardial depression of both ventricles via an 
impaired response of beta-receptors to en-
dogenous and exogenous catecholamines 
and via diminished sensitivity of contrac-
tile myofilaments to calcium. The results of 
the few investigator-initiated studies with 
levosimendan in septic shock support the 
possibility that levosimendan may have 
some beneficial effects in this highly vul-
nerable patient population.
Morelli et al. (81) randomly exposed 28 
septic patients with persisting left ventric-
ular dysfunction after 48 h of conventional 
treatment to receive a 24 h infusion of ei-
ther levosimendan (0.2 mg/kg/min, n=15) 
or dobutamine (5 mg/kg/min, n=13). In ad-
dition to improved haemodynamics, levo-
simendan increased gastric mucosal flow, 
creatinine clearance and urinary output 
and decreased lactate levels, without nega-
tively affecting mean arterial pressure. Re-
ports by the same author (72) of favourable 
effects of levosimendan in patients with 
sepsis-related ARDS have already been 
noted in this review (see section on “Right 
ventricular failure”). A 500-patient study 
sponsored by the NIHR-EME program is 
shortly to commence in the UK (led by Dr. 
A.C. Gordon in conjunction with the Im-
perial Clinical Trials Unit) assessing the 
role of Levosimendan for the Prevention of 
Acute oRgan Dysfunction in Sepsis (LeoP-
ARDS, ISRCTN12776039). This double-
blind randomised placebo-controlled trial 
will test if levosimendan, when added to 
standard of care, reduces multiple organ 
failure and improve patient outcome.
Levosimendan
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Weaning from ventilator
Acquired diaphragm muscle weakness is a 
key feature in several chronic conditions, 
including COPD and congestive heart fail-
ure, and patients who are difficult to wean 
from mechanical ventilation (82). About 
10-20% of intubated patients in ICUs are 
difficult to wean from mechanical ventila-
tion, resulting in increased morbidity, mor-
tality and health care costs (83).
The pathophysiology of muscle weakness 
in these patients is complex, but includes 
muscle fiber atrophy and reduced calcium 
sensitivity of the contractile proteins (84). 
As respiratory muscle troponin resembles 
cardiac troponin, it is plausible that levo-
simendan may enhance contractility in the 
same way it enhances cardiac contractility.
This supposition has support from in vitro 
data (58), experimental observations (85), 
and a healthy volunteer study (82). Posi-
tive effects were seen both in slow and rap-
id diaphragm muscle fibers (58, 85). 
Mechanical ventilation results in rapid loss 
of diaphragmatic force production (86). In 
addition, shifting from mechanical ventila-
tion to spontaneous ventilation may dra-
matically increase left ventricular filling 
pressure and pulmonary artery pressure, 
especially in patients with pre-existing car-
diac and or pulmonary comorbidities.
Levosimendan was compared to dobuta-
mine in difficult-to-wean COPD patients 
(87). Levosimendan resulted in signifi-
cantly greater inhibition of spontaneous 
ventilation induced increase in pulmonary 
artery occlusion pressure. Similarly, mean 
pulmonary artery pressure increased to a 
lesser extent with levosimendan than with 
dobutamine. In a prospective observational 
study in ventilator-dependent difficult-to-
wean ICU-patients with diminished left 
ventricular function (LVEF <40%), levo-
simendan improved cardiac contractility 
and oxygenation variables and increased 
the likelihood of separation from mechani-
cal ventilation (83). A study on the Effects 
of Levosimendan on Diaphragm Func-
tion in Mechanically Ventilated Patients 
(NCT01721434) run at the University 
Medical Center Nijmegen is currently re-
cruiting.
Cardiac surgery
Peri-operative acute cardiovascular dys-
function occurs in more than 20% of pa-
tients undergoing cardiac surgery; yet 
current AHF classification (68) is not ap-
plicable to this period. Indicators of major 
perioperative risk include unstable coro-
nary syndromes, decompensated heart fail-
ure, significant arrhythmias and valvular 
disease. Clinical risk factors include histo-
ry of heart disease, including heart failure, 
cerebrovascular disease, presence of diabe-
tes mellitus, renal insufficiency and high-
risk surgery (88).
Preserving heart function during cardiac 
surgery is a major goal. However, optimal 
perioperative use of inotropes and vaso-
pressors in cardiac surgery remains con-
troversial. Neither is the use of an IABP 
or left ventricular assist device (LVAD) 
risk-free (89, 90). The comparative data 
on levosimendan in this situation suggest 
that it has the potential to become a drug 
of choice among the agents with inotropic 
properties, possibly due to its cardioprotec-
tive qualities.
Several studies have demonstrated that le-
vosimendan protects the myocardium and 
improves tissue perfusion, while minimis-
ing tissue damage during the cardiac sur-
gery and reperfusion periods (20, 33, 91). 
Current data from individual studies and 
meta-analyses suggest that levosimendan 
is superior to traditional inotropes (dobu-
tamine, phosphodiesterase-inhibitors), de-
livering sustained haemodynamic improve-
ment, diminished myocardial injury, and 
better outcomes (92, 93).
Tritapepe et al. (94) performed a ran-
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domised, double-blind, placebo-controlled 
study in 106 patients undergoing elective 
multivesselcoronary artery bypass graft-
ing (CABG). Levosimendan (bolus only, 
24  μg/kg over 10 min), or placebo was 
given before initiation of cardiopulmonary 
bypass (CPB). Mean tracheal intubation 
time and length of ICU stay were signifi-
cantly shorter in the levosimendan group 
(both p<0.01) and the number of patients 
needing inotropic support for >12 h was 
significantly lower with levosimendan 
(18.0% vs 3.8%; p = 0.021). Significantly 
higher postoperative values of mean arte-
rial pressure, cardiac index and cardiac 
power index, and a lower systemic vascular 
resistance index were observed with levo-
simendan, while troponin I increases were 
significantly smaller (all p<0.005 or less).
In a placebo-controlled study in 60 patients 
undergoing CABG Eriksson et al. showed 
that levosimendan (0.2 µg/kg/min, 24 h) 
increases the success of primary weaning 
from CPB (73% vs 33%, p=0.002) (33).
Lahtinen et al. (95) reported a randomised, 
double-blind, placebo-controlled study in 
200 patients assigned to undergo heart 
valve or combined heart valve and CABG 
surgery. Levosimendan was given as a 24-h 
infusion started at the induction of anaes-
thesia with a 24 µg/kg bolus over 30 min 
and thereafter at a dose of 0.2 µg/kg/min. 
The primary outcome measure was heart 
failure, defined as cardiac index <2.0 l/
min/m2 or failure to wean from CPB ne-
cessitating inotrope administration for at 
least 2 hours postoperatively after CPB. 
Heart failure was less frequent in the levo-
simendan group than in the placebo group 
(15% vs 58%; p<0.001). Need of inotrope 
use for rescue was also lower in the levo-
simendan group (risk ratio 0.11; 95% CI 
0.01-0.89), and IABP was utilised in one 
patient (1%) in the levosimendan versus 
nine (9%) in the placebo group (risk ratio 
0.11; 95% CI 0.01-0.87). Creatine kinase 
was lower in the levosimendan group on 
the first post-operative day (p=0.011). 
The levosimendan group had more hypo-
tension and needed norepinephrine more 
often (83 vs 52, p<0.001). There was no 
difference in in-hospital or 6-month mor-
tality (overall, 12% of the patients died in 
both groups). 
The meta-analysis by Landoni et al. (40) 
on mortality with intravenous levosimen-
dan identified 17 studies in cardiac surgery, 
including 1233 patients. Levosimendan 
reduced mortality significantly in cardiac 
surgery patients compared with the control 
arms (5.8% vs 12.9%; risk ratio 0.52, 95% 
CI 0.35-0.76). 
In another independent meta-analysis, 
Maharaj and Metaxa (41) reported a fa-
vourable effects of levosimendan on car-
diac index (mean difference 1.63, 95% CI 
1.43-1.83, p<0.00001), length of ICU stay 
(mean difference -26 hours 95% CI -46 to 
-6, p=0.01), rate of atrial fibrillation (odds 
ratio 0.54, 95%  CI 0.36-0.82, p=0.004), 
and troponin I levels (mean difference 
-1.59, 95% CI 1.78-1.40, p<0.00001) as 
well as a mortality reduction after coronary 
revascularisation (odds ratio 0.40, 95% CI 
0.21-0.76, p=0.005). These data ampli-
fied the findings of previous meta-analyses 
(42,44,53). 
Recently, a group of experts published a
consensus report on how to use levosimen-
dan in cardiac surgery (30) and the study 
Levosimendan in High Risk Patients Un-
dergoing Cardiac Surgery (HSR-LEVO, 
NCT00994825) was initiated and is cur-
rently recruiting. Of interest also two re-
cent papers on reduction of perioperative 
mortality (96, 97) in which levosimendan 
is cited as a drug with potential to reduce 
mortality in surgical settings.
Non cardiac surgery
Congestive heart failure is a non-uncom-
mon co-morbidity in patients undergoing 
Levosimendan
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non-cardiac surgery, and is strongly associ-
ated with a doubling of the in-hospital mor-
tality (98). Some authors have suggested a 
role for levosimendan in the preoperative 
optimization of cardiac function in patient 
undergoing major elective non-cardiac sur-
gery (99). Katsaragakis et al. reported on 
the use of levosimendan in high risk pa-
tients undergoing abdominal surgery (100), 
while Ponschab et al. (101) described how 
levosimendan infusion improves haemo-
dynamics in elderly heart failure patients 
undergoing urgent hip fracture repair. 
Both groups demonstrated that the admin-
istration of levosimendan was safe and ob-
served improvements in ejection fraction, 
echochardiographic parameters as well as 
a range of haemodynamic indices both in-
tra- and postoperatively. Therefore, Morel-
li et al. suggested that the prophylactic ad-
ministration of levosimendan in patients 
with compromised myocardial physiologic 
reserve, undergoing anesthesia and major 
non-cardiac surgery, is safe and advisable 
for preoperative cardiac optimization (99).
Paediatric use
In the paediatric cardiac settings, inotro-
pic support is often employed on the basis 
of extrapolations from adult studies, the 
underlying pathophysiology, the pharma-
codynamics of inotropes, and anecdotal 
experience. There are currently no official 
indications for levosimendan in patients 
under 18 years of age (see levosimendan 
SPC), but the drug has been indeed studied 
and used as a rescue drug in the paediat-
ric ICU (PICU) and in the operating room. 
The published paediatric experience in le-
vosimendan comprises mainly observation-
al studies [see recent reviews by Hoffman 
(102) and by Angadi et al. (103)] or analy-
ses of patient registers (104), but also four 
randomised and blinded trials have been 
reported (105-108). All in all, 645 patients 
were included in 14 reports.
The pharmacokinetic profile of levosimen-
dan in children with congenital heart dis-
ease is similar to that in adult patients with 
congestive heart failure (109). Ten hours 
after the initiation of 48 hours levosimen-
dan infusion in neonates undergoing cardi-
ac surgery, the active metabolite OR-1896 
was detectable in plasma and remained 
measurable up to 14 days (106). This ob-
servation suggests that levosimendan will 
exert prolonged hemodynamic effects in 
neonates after cessation of infusion similar 
to those noted in adults.
As it regards the doses, levosimendan has 
been administered in children without or 
with a bolus dose of 6-24 mcg/kg, and by 
infusion of 0.05 to 0.2 mcg/kg/min similar-
ly to adults. Levosimendan infusions have 
been well tolerated in children with acute 
heart failure or children who are undergo-
ing cardiac surgery; only transient hypo-
tension or tachycardia has been reported 
in the beginning of the infusion. The larg-
est published data in paediatrics included 
retrospectively-gathered data on 484 levo-
simendan infusions delivered to 293 pa-
tients at a single PICU (104). A majority of 
the patients (65%) were aged 12 months or 
younger. Most of the physicians surveyed 
(89%) thought that levosimendan post-
poned or reduced the need for mechanical 
cardiac support in children with cardiomy-
opathy or who were undergoing cardiac 
surgery. Levosimendan was shown to be 
as efficacious as milrinone with compara-
ble hemodynamic data in two randomised 
and double-blind studies in children and in 
neonates undergoing cardiac surgery (107, 
110). In another comparison of milrinone 
and levosimendan in neonates undergoing 
cardiac surgery, levosimendan group had 
higher pH, lower blood glucose level and 
lower inotrope score in the PICU (106).
Finally, in a randomised double-blind study 
in children younger than 4 years of age un-
dergoing cardiac surgery, patients receiv-
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ing levosimendan had significantly higher 
cardiac index and lower pulmonary artery 
pressure than children receiving dobuta-
mine (108). Of interest is a report describ-
ing a strategy for rotating inotropes in pe-
diatric decompensated heart failure (111).
Other clinical settings
Case reports, uncontrolled small series or 
small-scale comparative studies with levo-
simendan have been published e.g. in cal-
cium-channels-blockers intoxication (112) 
and Takotsubo cardiomyopathy (113, 114).
concluSIon, GuIdAncE 
FoR clInIcAl uSE, 
FutuRE dEVEloPMEntS
Its pharmacologic and pharmacodynamic 
properties differentiate levosimendan from 
other inotropes. The infusion of levosi-
mendan has consistently been shown to 
enhance left ventricular performance and 
to decrease left ventricular filling pressure 
and plasma BNP concentrations without 
increasing myocardial oxygen consumption 
(Table 2). Neither age nor gender influence 
the responses to levosimendan. Following 
a 24 h infusion of levosimendan, the active 
metabolite reaches pharmacologically ac-
tive plasma levels, resulting in a prolonged 
haemodynamic effect (115, 116), wich per-
sists for at least 7 days (24). The haemody-
namic and neurohumoral improvement is 
associated with a symptomatic benefit that 
is sustained and superior to that of placebo. 
In contrast to dobutamine, the effects of 
levosimendan are not attenuated with con-
comitant beta-blocker use (26). In two early 
phase III studies, a significant mortality 
benefit with levosimendan was observed in 
comparison with both placebo (RUSSLAN) 
(34) and dobutamine (LIDO) (17). These 
favourable results were not, however, cor-
roborated by two subsequent studies where 
levosimendan was compared with placebo 
(REVIVE) (35) and dobutamine (SUR-
VIVE) (23). 
Subgroup analyses from the SURVIVE study 
indicate nevertheless that levosimendan 
outperforms dobutamine in betablocked 
patients and in patients with acute decom-
pensation of an existing chronic failure (26). 
Recent independent meta-analyses on the 
effect of levosimendan on mortality suggest 
a survival benefit of levosimendan both com-
pared to placebo and dobutamine; a trend 
towards a more favourable outcome effect 
was noted with lower levosimendan doses 
(≤ 0.1 µg/kg/min) (40). Dosing guidance for 
levosimendan in ADHF (Table 3) may be 
proposed from the experience of controlled 
trials. Levosimendan infusion has generally 
been well tolerated. 
Data from the REVIVE and SURVIVE stud-
ies - the two largest studies conducted to 
date - indicate that hypotension was more 
frequent with levosimendan than with pla-
cebo, though not dobutamine. Levosimen-
table 2 - Clinical effects of levosimendan.
Haemodynamic 
and neurohormonal 
effects
other clinical effects
Pulmonary capillary 
wedge pressure ↓↓↓
Relief of symptoms of 
heart failure
Cardiac output (index) 
↑↑
Effects maintained also 
with beta-blockers
Stroke volume ↑ Sustained effects due to 
an active metabolite
Systemic vascular 
resistance ↓↓
No development 
of tolerance
Pulmonary vascular 
resistance ↓↓
No increase in 
myocardial oxygen 
consumption
Natriuretic peptide 
levels ↓↓↓
Anti-ischemic effect
No impairment 
of diastolic function 
↓ = decrease, ↑ = increase
Levosimendan
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dan was also associated with higher inci-
dence of atrial fibrillation relative to both 
those comparators. 
It should be recalled that, in addition to con-
tractility increasing effects, levosimendan 
has profound vasodilatory effects. Clinical 
studies have indicated that levosimendan 
should be given cautiously to patients with 
low blood pressure, especially in case of hy-
povolaemia. 
Use of lower infusion rates without the load-
ing bolus should be considered for such pa-
tients. In case of unintended overdose, pro-
nounced haemodynamic effects would be 
expected; mainly hypotension and increased 
heart rate/arrhythmias. Hypotension should 
be treated with fluid resuscitation and vaso-
constrictors, as needed. Arrhythmias may 
be treated with intravenous beta-blockade 
or amiodarone (if blood pressure allows). 
Due to the formation of the active metabo-
lite, the follow-up may need to be prolonged, 
if the total dose of parent drug is substantial. 
Applications of this drug in fields such as 
cardiac and non-cardiac surgery, cardiogen-
ic- and septic-shock, and others have been 
proposed. 
The effects of levosimendan in these set-
tings have been described in many indepen-
dent studies, and there is a strong rationale 
for suitably powered studies to corroborate 
those reports. Positive experience in a range 
of niche applications has also been docu-
mented.
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